Black Diamond Therapeutics, Inc. (BDTX)
USD 2.34
(-6.4%)
USD 2.34
(-6.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -66.71 Million | -85.08 Million | -100.14 Million | -52.14 Million | -24.67 Million | -8.45 Million |
| Net Income | -82.44 Million | -91.16 Million | -125.59 Million | -67.25 Million | -35.25 Million | -8.93 Million |
| Depreciation & Amortization | 437 Thousand | 508 Thousand | 205 Thousand | 52 Thousand | 47 Thousand | 44 Thousand |
| Deferred income taxes | -597 Thousand | - | 2.17 Million | 1.72 Million | - | - |
| Stock-based compensation | 9.6 Million | 12.19 Million | 14.03 Million | 7.76 Million | 3.64 Million | 64 Thousand |
| Change in working capital | 3.68 Million | -9.9 Million | 7.02 Million | 5.04 Million | 463 Thousand | 354 Thousand |
| Other non-cash items | 2.59 Million | 3.28 Million | 2 Million | 524 Thousand | 6.43 Million | 15 Thousand |
| Investing Cash Flow | 16.34 Million | 53.36 Million | 130.61 Million | -281.69 Million | -21 Thousand | -76 Thousand |
| Investments in PPE | -33 Thousand | -192 Thousand | -2.71 Million | -142 Thousand | -21 Thousand | -76 Thousand |
| Acquisitions | 95 Thousand | 9000.00 | 2.7 Million | 118 Thousand | - | - |
| Investment purchases | -61.88 Million | -60.14 Million | -49.5 Million | -372.47 Million | - | - |
| Sales/Maturities of investments | 78.17 Million | 113.69 Million | 182.83 Million | 90.92 Million | - | - |
| Other Investing Activities | 16.37 Thousand | 53.55 Thousand | -2.7 Million | -118 Thousand | -21 Thousand | - |
| Financing Cash Flow | 71.93 Million | 177 Thousand | 729 Thousand | 214.94 Million | 127.75 Million | 52.31 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 71.93 Million | 177 Thousand | 729 Thousand | 214.94 Million | 129.49 Million | 52.31 Million |
| Other Financing Activities | 82 Thousand | 177.00 | 729.00 | 214.94 Million | -1.74 Million | 52.31 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 597 Thousand | -2.23 Million | 1.56 Million | 1.06 Million | 1.45 Million | 264 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 3.08 Million | -7.67 Million | 5.45 Million | 3.97 Million | -991 Thousand | 90 Thousand |
| Cash at beginning of period | 34.31 Million | 67.02 Million | 35.82 Million | 154.72 Million | 51.66 Million | 7.87 Million |
| Cash at end of period | 56.22 Million | 35.48 Million | 67.02 Million | 35.82 Million | 154.72 Million | 51.66 Million |
| Capital Expenditure | -33 Thousand | -192 Thousand | -2.71 Million | -142 Thousand | -21 Thousand | -76 Thousand |
| Effect of forex changes on cash | 345 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | 21.9 Million | -31.53 Million | 31.19 Million | -118.89 Million | 103.06 Million | 43.78 Million |
| Free Cash Flow | -66.75 Million | -85.27 Million | -102.85 Million | -52.28 Million | -24.69 Million | -8.53 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -15.55 Million | -19.9 Million | -18.22 Million | -19.4 Million | -82.44 Million | -23 Million |
| Depreciation & Amortization | 86 Thousand | 86 Thousand | 86 Thousand | 86 Thousand | 437 Thousand | 115 Thousand |
| Deferred income taxes | - | - | - | -78 Thousand | -597 Thousand | -170 Thousand |
| Stock-based compensation | 1.99 Million | 5.28 Million | 1.71 Million | 1.53 Million | 9.6 Million | 2.75 Million |
| Change in working capital | 4.35 Million | 217 Thousand | -4.56 Million | 3.92 Million | 3.68 Million | 1.24 Million |
| Other non-cash items | -2.19 Million | 5.48 Million | 2.8 Million | -17 Thousand | 2.59 Million | 708 Thousand |
| Investing Cash Flow | 2.19 Million | 740 Thousand | -13.73 Million | 12.24 Million | 16.34 Million | -37.88 Million |
| Investments in PPE | -14.72 Million | 14.72 Million | - | 33 Thousand | -33 Thousand | -33 Thousand |
| Acquisitions | -38 Thousand | 38 Thousand | - | -132.85 Thousand | 95 Thousand | 37.85 Thousand |
| Investment purchases | -27.85 Million | -39.79 Million | -52.23 Million | -15.78 Million | -61.88 Million | -46.1 Million |
| Sales/Maturities of investments | 30 Million | 40.5 Million | 38.5 Million | 28.03 Million | 78.17 Million | 8.25 Million |
| Other Investing Activities | 14.81 Million | 740 Thousand | -13.73 Million | 12.24 Thousand | 16.37 Thousand | -37.85 Thousand |
| Financing Cash Flow | -252 Thousand | 21.37 Million | 4.13 Million | -46 Thousand | 71.93 Million | 71.92 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -46.00 | - | - |
| Common Stock Issuance | -1.01 Million | 21.37 Million | 4.13 Million | -46 Thousand | 71.93 Million | 71.92 Million |
| Other Financing Activities | 762 Thousand | 21.37 Million | 4.13 Million | 82 Thousand | 82 Thousand | 71.92 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.2 Million | -433 Thousand | -1.12 Million | 1.63 Million | 597 Thousand | -1.85 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.79 Million | 650 Thousand | -3.44 Million | 2.29 Million | 3.08 Million | 3.1 Million |
| Cash at beginning of period | 32.81 Million | 25.42 Million | 56.22 Million | 57.97 Million | 34.31 Million | 43.11 Million |
| Cash at end of period | 24.25 Million | 32.81 Million | 25.42 Million | 56.22 Million | 56.22 Million | 58.79 Million |
| Capital Expenditure | -14.72 Million | 14.72 Million | - | 33 Thousand | -33 Thousand | -33 Thousand |
| Effect of forex changes on cash | - | - | - | -4000.00 | 345 Thousand | - |
| Net cash flow / Change in cash | -8.56 Million | 7.38 Million | -30.79 Million | -1.75 Million | 21.9 Million | 15.68 Million |
| Free Cash Flow | -26.04 Million | - | -21.19 Million | -13.92 Million | -66.75 Million | -18.39 Million |
RNK
601228
HXCK
003029
ASTTF
SPOG